The IMbrave150 trial (NCT03434379) assessed the combination of atezolizumab (anti-PD-L1) and bevacizumab (VEGF inhibitor) versus sorafenib in the treatment of patients with advanced HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.